This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Overactive Bladder Overview
- Therapeutics Development
- Pipeline Products for Overactive Bladder - Overview
- Pipeline Products for Overactive Bladder - Comparative Analysis
- Overactive Bladder - Therapeutics under Development by Companies
- Overactive Bladder - Therapeutics under Investigation by Universities/Institutes
- Overactive Bladder Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Overactive Bladder - Products under Development by Companies
- Overactive Bladder - Products under Investigation by Universities/Institutes
- Overactive Bladder - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Asahi Kasei Pharma Corp.
- Astellas Pharma Inc.
- Dompe Farmaceutici S.p.A.
- FemmePharma Global Healthcare, Inc.
- Hydra Biosciences, Inc.
- Ion Channel Innovations, LLC
- Jeil Pharmaceutical Co., Ltd.
- Juniper Pharmaceuticals, Inc.
- Lipella Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Mezzion Pharma Co. Ltd.
- MI.TO. Technology S.r.L.
- Recordati S.p.A.
- Sihuan Pharmaceutical Holdings Group Ltd.
- Taris Biomedical LLC
- TheraVida, Inc.
- Toray Industries, Inc.
- UroGen Pharmaceuticals, Ltd.
For more information visit http://www.researchandmarkets.com/research/ncd993/overactive